MabVax Therapeutics Holdings Inc
MabVax Therapeutics — Investor Presentation (March 2017)
57 slides from MabVax Therapeutics's investor presentation, Mar 29, 2017

Slide 1: MabVax Therapeutics March 2017 Presentation
L NASDAQ: MBVX NY, | MabVax therapeutics Clinical Stage Immuno-Oncology Company Developing Unique Human Monoclonal Antibody- Based Products for Difficult to Treat Cancers March 2017 Presentation David Hansen, President and CEO

Slide 2: Disclaimer
DISCLAIMER Forward Looking Statements This presentation contains forward-looking statements and projections. The company makes no express or implied representation or warranty as to the completeness of this information or, in the case of the projections, as to their attainability or the accuracy and

Slide 3: MabVax Therapeutics Overview
MABVAX THERAPEUTICS OVERVIEW Fully-human antibody discovery platform Focused on rapid translation of discoveries into clinical development Integrated approach to development Development pathway to Phase IT studies Key collaborations M MabVax W therapeutics Products discovered from immune responses o

Slide 4: Remarkable Clinical and Scientific Progress on Unique Therapeutic and Diagnostic Products
REMARKABLE CLINICAL AND SCIENTIFIC PROGRESS ON UNIQUE THERAPEUTIC AND DIAGNOSTIC PRODUCTS MVT-5873 clinical tri demons and efficacy MVT-2163 clinical trial demonstrates early safety and specificity MVT-1075 clinical trial authorized by FDA Expansion to additional cers expr ssing same target an Secon

Slide 5: MabVax Has Rich Pipeline of Product Candidates
MABVAX HAS RICH PIPELINE OF PRODUCT CANDIDATES Program MVT-5873 Therapeutic Monotherapy MVT-5873 Therapeutic Combination with soc MVT-2163 PET-Imaging MVT-1075 Radio- immunotherapy HuMab 5B1-ADC. HuMab 5B1- Fe Optimization Additional HuMab Antibodies in Early Development M MabVax therapeutics Indica

Slide 6: Summary of Preclinical Data
SUMMARY OF PRECLINICAL DATA M MabVax NASDAQ: MBVX therapeutics 6

Slide 7: Sialyl Lewis A as a Viable Target for Cancer Therapeutics
SIALYL LEWISs4 — AS A VIABLE TARGET FOR CANCER THERAPEUTICS ¢@ HuMab-5B1 derived from a patient vaccinated with MabVax vaccine licensed from MSKCC CA19-9 detection in patients 4 @ Sialyl Lewis A antigen (SLEA or CA19-9) is the most frequently utilized and only Pancreas 92 validated serum marker for

Slide 8: Binding of Anti-SLEA mAbs to Multiple Tumor Cells
BINDING OF ANTI-SLE4 MABS TO MULTIPLE TUMOR CELLS A DMS79 Raila ee ‘i " A SCLC ‘ 15B1 r5HI1 |. eS Gee c. Pancreas FE ) \ Ly D. Ovary 24 f\ wt | = wt E Melanoma oF alli, | Flite} = iB on B. HT29 Cc. BxPC3 —_ wesiee a —_ 3. 3. % r5B1 17E3 r5B1 17E3 \ 7 yaaa Tien" "one oe raneae roan open ree Spanier h

Slide 9: HuMab-5B1 Is Highly Specific to SLEA Antigen by Glycan Array Analysis
HUMAB-5B1 Is HIGHLY SPECIFIC TO SLE* ANTIGEN BY GLYCAN ARRAY ANALYSIS ‘Consortium for Functional Glycomics i * Novel fully-human IgG1 antibody | = ° Exceptional specificity i ce * Very good affinity (0.14nM) , ed * No cross-reactivity with related © ee accents: carbohydrate structures * CDC and ADCC

Slide 10: CA19-9 Positive Malignancies Present Broad Therapeutic Target
CA19-9 POSITIVE MALIGNANCIES PRESENT BROAD ‘THERAPEUTIC TARGET FOR HUMAB-5B1 ANTIBODY THERAPIES ¢ Tissue microarray used to survey therapeutic pathways for HuMab-5B1 program ¢ Includes human patient tissues and cores from xenograft models ¢ Positive results include pancreatic, small cell lung, gastr

Slide 11: HuMab-5B1 Is Internalized into Target Cells
HUMAB-5B1 Is INTERNALIZED INTO TARGET CELLS Internalization Occurs Rapidly and Varies Between Cell Lines Assay Principle * The pH sensitive dye pHAb that becomes fluorescent at low pH encountered in endosomes is conjugated to MVT-5873 or anti-human F(ab),. BxPC3 % Poritve * The percentage of fluores

Slide 12: Non-Clinical Safety Studies Supporting MVT-5873
NON-CLINICAL SAFETY STUDIES SUPPORTING MVT-5873 GLP in vitro tissue cross-reactivity studies with human and cynomolgus tissues ¢ Staining similar in human and cynomolgus providing toxicology species justification @ Staining observed in epithelial cell types and related extracellular mucus-like mater

Slide 13: MVT-5873 Demonstrates Synergistic Anti-Tumor Effect with Chemotherapy
MVT-5873 DEMONSTRATES SYNERGISTIC ANTI- TUMOR EFFECT WITH CHEMOTHERAPY IN MULTIPLE CANCER MODELS Relative Tumor Growth at Day 42 Relative Tumor Volume at Day 52 Gemcitabine/nab-Paclitaxel as Baseline BxPC3 Pancreatic Xenograft Model Paclitaxel as Baseline DMS 79 SCLC Xenograft Model = 2500 ) S Hates

Slide 14: MVT-5873 Clinical Program Summary and Interim Data
MVT-5873 CLINICAL PROGRAM SUMMARY AND INTERIM DATA M MabVax NASDAQ: MBVX therapeutics 14

Slide 15: MVT-5873 Phase I Trial for PDAC & CA19-9 Positive Cancer
MVT-5873 PHASE I TRIAL FOR PDAC & CA19-9 POSITIVE CANCER Open label, non-Randomized, Dose Escalation/Expansion Study Part 2: Combination with Chemotherapy (gemcitabine/nab-paclitaxel) Part 1: Single Agent Dose Escalation Stage 3 and 4 Patients With Progressive Disease Who Have Failed Other Treatment

Slide 16: Interim MVT-5873 Pharmacokinetics Analysis
INTERIM MVT-5873 PHARMACOKINETICS ANALYSIS PARAMETERS SIMILAR TO OTHER THERAPEUTIC ANTIBODIES ¢ The study is evaluating the pharmacokinetics of MVT-5873 in all cohorts ¢ Initial pharmacokinetic analysis includes evaluating different schedules of administration using a two-compartment model ¢@ MVT-58

Slide 17: Interim Analysis Shows MVT-5873 Normalizes CA19-9 Levels
INTERIM ANALYSIS SHOWS MVT-5873 NORMALIZES CA19-9 LEVELS IN PANCREATIC CANCER PATIENTS Circulating Levels of Antigen Normalized at Modest Doses of Antibody MVT-5873 Dose and Administration '% CA19-9 Reduction (>95%, Normal) Phe ghabeaae @ CA19-9 normalization post MVT-5873 administration appears to

Slide 18: Clinical Results to Date by Patient
CLINICAL RESULTS TO DATE (03/07/17) BY PATIENT RECIST 1.1 RECIST 1.1 RECIST 1.1 —_ 9 of 25 Stable at cycles/1 RECIST Assessment Pe Patients 5 of 25 Stable at 4 cycles/2 RECIST Assessments 3 of 25 Stable at 3 cycles/3 RECIST Assessments i | I I oo. 4 5 6 7 8 Time since start of treatment (months) @ S

Slide 19: Unmet Clinical Need for Maintenance Therapy
UNMET CLINICAL NEED FOR MAINTENANCE THERAPY ¢ Unmet need to extend and reinforce favorable results with induction therapies — Emerging strategies for long term control include pauses in therapy, re-challenges, and maintenance therapy — Commonly employed strategies are: * Switch to non-cross-resistan

Slide 20: Value of New Maintenance Therapy for Pancreatic Cancer
VALUE OF NEW MAINTENANCE THERAPY FOR PANCREATIC CANCER ¢ Only one comparison product approved for second line therapy: Merrimack’s ONIVYDE — Liposomal irinotecan and used only in combination with fluorouracil and leucovorin — OS improvement to 6.1 mos vs 4.2 mos and PFS improvement to 3.1 mos vs. 1.

Slide 21: MVT-2163 Clinical Program Summary and Interim Data
MVT-2163 CLINICAL PROGRAM SUMMARY AND INTERIM DATA M MabVax NASDAQ: MBVX therapeutics 21

Slide 22: MVT-2163 Preclinical Development Efforts Translated into Positive Clinical Results
MVT-2163 PRECLINICAL DEVELOPMENT EFFORTS HAVE TRANSLATED INTO POSITIVE CLINICAL RESULTS ¢ Based on in-depth review of clinical literature and input from thought leaders MabVax developed a rationale for a translational preclinical development plan to define: — Time required to obtain optimal scan ima

Slide 23: MVT-2163 Imaging Compared to Standard PET Agent
MVT-2163 IMAGING COMPARED TO STANDARD PET AGENT Mice orthotopically transplanted with BxPC3-luc pancreatic tumor xenografts JNM Rivers ‘The co-tegistration of FDG-PET and computed Acquired "Zr radiolabed-5B1 antibody (*°Z-5B1) tomography (CT) (left) and planar sections of PET image of the same mouse

Slide 24: 89Zr-HuMab-5B1 Tumor Targeting in Shedding and Non-Shedding Models
89ZR-HUMAB-5B1 TUMOR TARGETING OCCURS IN BOTH SHEDDING AND NON-SHEDDING CA19-9 MODELS DMS79 (SCLC) Does not shed detectable CA 19-9 2h 24h 48h 96h 120h Colo205 (Colon Cancer) High levels of shed antigen ~2300 U/ml for a 250mm? tumor Viola-Villegas, JNucMed 2013 \\/ NASDAQ: MBVX | 24 Wy therapeutics

Slide 25: MVT-5873 Pre-Administration Improves MVT-2163 PET Image Quality
MVT-5873 PRE-ADMINISTRATION IMPROVES MVT-2163 PET IMAGE QUALITY Ne ete? }- . Inject radiolabeled ee . ™ . v ee ec: : Tumor Cells. Zr-SB1 Basia ae uptake and Tumor irr Capan-2 Xenografted Mice Interval between injections B5m Binh G4nr 24h No “cold” > a poor contrast ] 2 Inje gs inject unlabeled * ant

Slide 26: Phase I Trial Design of MVT-2163 ImmunoPET Imaging Agent
PHASE I TRIAL DESIGN OF MVT-2163 IMMUNOPET IMAGING AGENT PANCREATIC CANCER AND OTHER CA19-9 MALIGNANCIES Open label, non-randomized, dose escalation/expansion study Patients can roll to MVT-5873 Monotherapy Trial lation and . Part 1: Dose Escalation Pareds Be Image Optimization MVT-2163 dosed alone,

Slide 27: Background: Comparable Antibody Therapies for Cancer Diagnosis and Treatment
BACKGROUND: COMPARABLE ANTIBODY THERAPIES FOR CANCER DIAGNOSIS AND TREATMENT 8°Z1-Trastuzumab for metastatic M1J-J591 for hormone Minibody *-Zr-DF IAB2M, breast cancer refractory prostate cancer 50mg pre-administration a —_— b _ ce = j ! 4 4 w i q | | ; ; 1 day ‘2 days 5 days ie — ba] ena Accumulati

Slide 28: 89Zr-DFO-HuMab5B1 (MVT-2163) Liver PET Images
89ZR-DFO-HUMAB5B1 (MVT-2163) LIVER PET IMAGES Dose Level: 50mg/4.43 mCi +Patient: Female 158cm/64.2kg Pre-Dose CA19-9 = 2119 IU/mL, Post Dose CA19-9 = 51 IU/mL 1h 20h 44h 141h Mi MabvVax NASDAQ: MBVX 28

Slide 29: Patient Example: MVT-2163 PET Images
PATIENT EXAMPLE: MVT-2163 PET IMAGES LIVER METASTASIS AT HIGH SUV AS EARLY AS Day 1 POST DOSE MVT-2163 PET & Diagnostic CT Image Correlation Demonstrating Target Specificity Liver metastases SUVmax 75.2, Multiple nodes SUVmax 10.2 MVT-5873 47mg then 2h delay time MVT-2163 PET PET / Cr | 20h 141h Dia

Slide 30: MVT-2163 Biodistribution
MVT-2163 BIODISTRIBUTION COMPARABLE WITH j591 AND JAB2M MINIBODY TRACERS 3.0 = OIAb2M. ao @J591 250 =5B1 (0) S o o ° fa] Sag 3° ao 2 ¢ 00 alitit alidal Ss & & eS ss ss YE SEPE Ly my rs ~ S M MabVax Patient #9 NASDAQ: MBVX | 30 therapeutics

Slide 31: Significant Accumulation of Antibody on Targeted Cancer
SIGNIFICANT ACCUMULATION OF ANTIBODY ON TARGETED CANCER MVT-2163 Accumulates on Target without interference by CA19-9 Levels Patient administered 3 mg MVT-2163 Patient administered 3 mg MVT- (no MVT-5873 loading dose) 2163 (47 mg MVT-5873 loading dose) 3 ry % 30 as Eos ? 5% a ver eson 21s = we Misin

Slide 32: MVT-2163 Product Opportunity
MVT-2163 PRODUCT OPPORTUNITY MVT-2163 images tumor lesions not identified by diagnostic CT Staging newly diagnosed PDAC patients for surgery is limited by CT resolution — Only 20% deemed eligible for surgery and majority found inoperable during surgery — Problem: Incomplete disease dissemination ide

Slide 33: MVT-1075 Program Summary and Product Opportunity
MVT-1075 PROGRAM SUMMARY AND PRODUCT OPPORTUNITY M MabVax NASDAQ: MBVX therapeutics 33

Slide 34: MVT-1075 Is Designed to Attack Primary Tumor and Metastatic Sites
MVT-1075 Is DESIGNED TO ATTACK PRIMARY TUMOR AND METASTATIC SITES Attribute Differentiation eetiened by MVT-2163 ] tumor normal \\/ NASDAQ: MBVX | 34 Wom Wf therapeutics

Slide 35: MVT-1075 Designed to Attack Primary Tumor and Metastatic Sites and Enhance Cell Death
MVT-1075 Is DESIGNED TO ATTACK PRIMARY TUMOR AND METASTATIC SITES AND ENHANCE CELL DEATH Highly specific HuMab-5B1 antibody conjugated to 177 radionuclide Lu MVT-2163 Phase I results demonstrate significant accumulation on tumor Rapid and significant internalization of antibody- radionuclide Effecti

Slide 36: MVT-1075 Radioimmunotherapy Preclinical Studies Demonstrate Tumor Growth Suppression
MVT-1075 RADIOIMMUNOTHERAPY — PRECLINICAL STUDIES DEMONSTRATE SUBSTANTIAL TUMOR GROWTH SUPPRESSION AND TUMOR REGRESSION fe 377Lu-CHX-A"-DTPA-5B1 Biodistribution of !”7 Lu-CHX-A”-DTPA-5B1 © Control (PBS) = 5B1 2 set df 130 2 = 300uCi 120 & io] * RO 110. , Bth 3 400 3 N=8 for all groups ° 80 2 ry es B

Slide 37: MVT-1075 Orthotopic PDAC Model Demonstrates Tumor Regression
MVT-1075 HUMAB-5B1 RADIOIMMUNOTHERAPY ORTHOTOPIC PDAC MODEL DEMONSTRATES TUMOR REGRESSION BO Pre-treatment Post-treatment Collaboration with Jason S. Lewis, Ph.D. Member, Memorial Sloan-Kettering Cancer Center, Mi Vice Chairman & Chief Attending, Department of Radiology MabVax NASDAQ: MBVX | 37

Slide 38: Manufacturing, Quality, Distribution Established for Clinical Program
MANUFACTURING, QUALITY, DISTRIBUTION ESTABLISHED FOR CLINICAL PROGRAM AND PATHWAY FOR COMMERCIALIZATION @ MVT-1075 manufactured on a per patient basis ¢ Manufacturing established at experienced cGMP third party site ¢ Produced from a bulk conjugate intermediate as unit-of-use vials @ Process similar

Slide 39: Phase I Trial of MVT-1075 Radioimmunotherapy
PHASE I TRIAL OF MVT-1075 RADIOIMMUNOTHERAPY FOR PANCREATIC AND OTHER CA19-9 MALIGNANCIES Open label, Non-randomized, Dose Escalation Safety Study blish Safety, Tolerability, Dosimetry & RP2D o-administration MVT-1075 fractional dose Phase I Dose E ion and Expansion Histologically confirmed, 3 study

Slide 40: MVT-1075 Unique Product with Significant Value Proposition
MVT-1075 UNIQUE PRODUCT WITH SIGNIFICANT VALUE PROPOSITION Compelling preclinical blished with 2163 High unmet medical Few doses to deliver full therapeutic impact Opportunity to expand to other cancer types Mivesvex Wom W therapeutics Single doses of MVT-1075 demonstrate tumor regression in animal

Slide 41: MVT-1075 Product Opportunity
MVT-1075 PRODUCT OPPORTUNITY ¢ Reduce disease burden by making more patients eligible for surgery — Given to newly diagnosed patients either before or after chemotherapy to reduce primary tumor size/spread and eliminate metastatic sites ¢ Applicable for multiple cancer types that are positive for CA

Slide 42: Value Proposition for a New Radioimmunotherapy for Pancreatic Cancer
VALUE PROPOSITION FOR A NEW RADIOIMMUNOTHERAPY FOR PANCREATIC CANCER ¢ Algeta’s Xofigo for castration-resistant prostate cancer — Xofigo (radium Ra 223) is radiotherapeutic alpha particle emitting product — Approved in US in May 2013 and EU in November 2013 — Development and commercialization deal w

Slide 43: HuMab-5B1-Based Antibody Drug Conjugate (ADC)
HUMAB-5B1-BASED ANTIBODY DRUG CONJUGATE (ADC) ve & @ HuMab-5B1 has ideal characteristics i“ inom for ADC novraes maacemine ¢ Antibody is readily internalized ¢ Large number of targets on each cell @ Proof of concept already demonstrated ¢ Multiple linker/toxin combinations are being evaluated to ide

Slide 44: HuMab-5B1-ADC Demonstrates Efficacy in Multiple Tumor Cell Lines and Models
HUMAB-5B1-ADC DEMONSTRATES EFFICACY IN MULTIPLE TUMOR CELL LINES AND ANIMAL CANCER MODELS HuMab-5B1 Antibody Drug Conjugate In Vivo Linker Optimization Study Demonstrates Efficacy 1600.00 Mean Tumor Volume 500.00 400.00 300.00 200.00 100.00 0.00 -*PBS -—® ADC1 -*- ADC2 —- ADC3 -®ADC4 —ADC5 M MabVax

Slide 45: Market Opportunity for HuMab 5B1
MARKET OPPORTUNITY FOR HUMAB 5B1 — REPRESENTS POTENTIAL NEW TREATMENTS FOR MULTIPLE CANCERS Pancreatic Colon & Rectum Small Cell Lung Cancer Stomach Mi MabVax therapeutics 53,070 134,490 30,143 26,370 Deaths Yr /Y u 41,780 7.7% 49,119 65% 20,100 14% 10,730 31% ' Global Data Disease Reports Market Op

Slide 46: Partnering Discussions
PARTNERING DISCUSSIONS ¢ Active discussions with potential partners under CDA in progress. Multiple opportunities ¢ Antibody as targeting vehicle for development of a bi-specific, ADC or CAR-T product — Multiple domestic and Asian companies — Multiple indications ¢ Radioimmunotherapy product — Multi

Slide 47: Key Milestones for HuMab5B1 Development Programs
Key MILESTONES FOR HUMAB5B1 DEVELOPMENT PROGRAMS FOR 2016 AND 2017 ° 1H2016 2H2016 1H2017 2H2017 Program MVT-5873 Y Initiate dose Y Early readouton * Complete * Full Phase I trial Therapeutic escalation safety ies, PK, dose enrollment and result available Monotherapy Phase I Trial report at scientif

Slide 48: Focused on Building Shareholder Value Near Term
FOCUSED ON BUILDING SHAREHOLDER VALUE NEAR TERM 1. Encouraging data emerging from two clinical trials 2. Complete MVT-5873 phase Ia therapeutic clinical study and present data early in 2017. Define recommended phase II dose (RP2D) 3. Launch Phase 5873 phase Ib POC for maintenance treatment in PDAC 4

Slide 49: Robust Intellectual Property
ROBUST INTELLECTUAL PROPERTY 14 issued patents and 3 pending applications in the U.S. ¢ 13 issued US patents and 1 pending US application covering monovalent and polyvalent vaccines, methods of manufacture, methods of use ¢ 1 issued US patent and 2 pending US applications covering monoclonal antibod

Slide 50: Strong Management Team and Board of Directors
STRONG MANAGEMENT TEAM AND BOARD OF DIRECTORS J. David Hansen Founder, President & CEO Board Member Philip Livingston, M.D. Founder & Chief Science Officer Gregory Hanson Chief Financial Officer Wolfgang Scholz, Ph.D. Founder & Vice President Antibody Discovery Paul Maffuid, Ph.D. Executive Vice Pre

Slide 51: Capitalization Table / Financial Statistics
CAPITALIZATION TABLE/ FINANCIAL STATISTICS Security Common Shares - Outstanding = 6.3M Preferred Stock — Common Equivalents ($0.01 Liquidation Preference) 7 20M Subtotal - 9.3M Restricted Stock Units — Outstanding and Unvested - 0.2M Warrants - Outstanding $6.84 5.1M Stock Options — Outstanding and

Slide 52: Market Statistics
MARKET STATISTICS* Stock Symbol: MBVX (Nasdaq Capital Market) Closing Price: $2.27 on March 24, 2017 52 Week High/Low: $6.05/$2.25 3-Month Average Daily Volume/Liquidity 63,000/$142,000 Shares Outstanding: 6.3 Million™ Market Cap: $14.3 Million™ Float: 6.0 Million Free Trading Shares *Price & Volume

Slide 53: Company Contacts
Mi MabVax therapeutics Immuno-Oncology Products Discovered From The Human Immune Response to Cancer Company Contacts J. David Hansen Gregory P. Hanson CMA MBA President and CEO Chief Financial Officer dhansen@mabvax.com gregoryhanson@mabvax.com 858-500-8455 858-500-8457 Mu Vax NASDAQ: MBVX | 53

Slide 54: Interim Analysis Shows MVT-5873 Normalizes CA19-9 Levels
INTERIM ANALYSIS SHOWS MVT-5873 NORMALIZES CA19-9 LEVELS IN PANCREATIC CANCER PATIENTS Circulating Levels of Antigen Normalized at Modest Doses of Antibody # CA19-9 normalization post MVT- 1mg/kg 2mg/kg 5873 administration appears to be Per Dose Per Dose Pre-Dose Levels dose dependent ¢# 1 mg/kg MVT

Slide 55: Interim Analysis Shows MVT-5873 Normalizes CA19-9 Levels
INTERIM ANALYSIS SHOWS MVT-5873 NORMALIZES CA19-9 LEVELS IN PANCREATIC CANCER PATIENTS Circulating Levels of Antigen Normalized at Modest Doses of Antibody ¢@ CA19-9 normalization post MVT-5873 administration appears to be dose dependent ¢# 1 mg/kg MVT-5873 appears to normalize elevated CA19-9 level

Slide 56: HuMab-5B1 Antibody Target Significantly Overexpressed on Multiple Cancers
HUMAB-5B1 ANTIBODY TARGET SIGNIFICANTLY OVEREXPRESSED ON MULTIPLE CANCERS Potential therapeutic utility extends beyond pancreatic cancer A. Pancreatic ductal adenocarcinoma & B. Colon carcinoma C. Lung adenocarcinoma D. Urinary bladder, mucinous adenocarcinoma E. Colon metastatic to ovary F. Breast

Slide 57: Sialyl Lewis A as a Viable Target for Cancer Therapeutics
SIALYL LEWIs4 — AS A VIABLE TARGET FOR CANCER THERAPEUTICS Validated tumor marker . . . 3; for PDAC and other Three increasing dosing cohorts cleared. 30% of late stage subjects treated achieve stable disease. Dosage levels cleared support full platform CA19-9 expressing tumors Significant number of
Source: SEC EDGAR · 8-K filed Mar 29, 2017
More decks from MabVax Therapeutics Holdings Inc
Investor Presentation (October 2018)19 slides · Oct 22, 2018
Virtual Investor Conference (May 2018)25 slides · May 3, 2018
Investor Presentation (February 2018)24 slides · Feb 12, 2018
Investor Presentation (September 2017)33 slides · Sep 12, 2017
Investor Presentation (August 2017)33 slides · Aug 24, 2017
Investor Presentation (June 2017)23 slides · Jun 23, 2017